Related Experiment Video
Updated: Aug 2, 2025

Isolation of Neonatal Extrahepatic Cholangiocytes
Published on: June 5, 2014
Expanding the phenotypic landscape of Gaucher disease type 3c with a novel entity - Transient neonatal cholestasis
Fatma Derya Bulut1, Deniz Kor1, Sebile Kılavuz2
1Çukurova University, Pediatric Metabolism and Nutrition Department, Adana, Turkey.
Insights
Gaucher disease type 3c, a cardiovascular phenotype of Gaucher disease, shows significant clinical heterogeneity. Transient neonatal cholestasis is identified as a novel finding in this rare lysosomal storage disorder.
Area of Science:
- Genetics and rare diseases
- Lysosomal storage disorders
- Cardiovascular manifestations of genetic disorders
Background:
- Gaucher disease (GD) is a frequent lysosomal storage disorder caused by GBA gene variants.
- Gaucher disease type 3c is specifically linked to the homozygous D409H variant, presenting a cardiovascular phenotype.
- Understanding the heterogeneity of GD type 3c is crucial for patient management.
Purpose of the Study:
- To describe the phenotypic heterogeneity of Gaucher disease type 3c.
- To report a novel clinical finding in patients with GD type 3c.
- To explore the association between age of onset and clinical presentation in GD type 3c.
Main Methods:
- Descriptive study of 13 patients with Gaucher disease type 3c.
- Clinical data collection on various organ system involvements.
- Phenotypic analysis and comparison based on age of onset.
Main Results:
- Patients exhibited diverse manifestations including visceral (100%), hematological (92.3%), neurological (92.3%), cardiac calcifications (84.6%), and corneal opacities (76.9%).
- Cervical dystonia (38.4%) and psychiatric disorders (46.1%) were common neurological findings.
- Transient neonatal cholestasis (38.4%) was identified as a novel finding in GD type 3c.
Conclusions:
- Gaucher disease type 3c presents with significant clinical heterogeneity.
- Age at onset correlates with specific clinical manifestations, with earlier onset primarily affecting visceral and hematological systems, and later onset involving cardiac, neurological, and psychiatric aspects.
- Further understanding of GD type 3c pathophysiology can guide targeted therapies for this fatal condition.
Abstract:
Gaucher disease (GD) is the most frequent lysosomal storage disorder due to biallelic pathogenic variants in GBA gene. Only homozygous D409H variant has been associated with the cardiovascular phenotype which is also known as Gaucher disease type 3c. In this descriptive study, we presented phenotypic heterogeneity and a novel clinical finding among 13 patients with GD type 3c. Patients presented with varying degrees of cardiac valve and/or aortic calcifications (84,6%) and corneal opacities (76,9%) in addition to visceral (100%), hematological (92,3%), neurological (92,3%), and skeletal (30%) manifestations. Also, cervical dystonia (38,4%) and psychiatric disorders (46,1%) were not infrequent entities with respect to neurological involvement in GD type 3c. In this report, we highlight transient neonatal cholestasis (38,4%) as a novel finding in GD type 3c. Neonatal cholestasis is a finding associated with Gaucher type 2, but transient neonatal cholestasis has not been reported in GD patients, so far. The clinical features of GD type 3c are highly heterogeneous, from disease severity or age of onset to disease progression. Also, we concluded that phenotypic spectrum may be associated with age at onset of clinical symptoms. As, patients presenting in infancy or childhood had mainly visceral and hematological involvement and patients presenting in adolescence and adulthood had mainly cardiac, neurological involvement, and psychiatric behavioral disorders. Identifying the heterogeneous clinical course of these patients in this fatal disease, may lead a sufficient understanding of the pathophysiology which will enable targeted therapeutic interventions.
More Related Videos
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Related Concept Videos
Lysosomal Hydrolases
Inborn Errors of Metabolism
Chronic Pancreatitis II: Collaborative Care
Assessment: